NO973404L - Human interleukin-1 receptor accessory protein - Google Patents

Human interleukin-1 receptor accessory protein

Info

Publication number
NO973404L
NO973404L NO973404A NO973404A NO973404L NO 973404 L NO973404 L NO 973404L NO 973404 A NO973404 A NO 973404A NO 973404 A NO973404 A NO 973404A NO 973404 L NO973404 L NO 973404L
Authority
NO
Norway
Prior art keywords
accessory protein
receptor accessory
human interleukin
protein
receptor
Prior art date
Application number
NO973404A
Other languages
Norwegian (no)
Other versions
NO973404D0 (en
Inventor
Richard Anthony Chizzonite
Grace Wong Ju
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO973404D0 publication Critical patent/NO973404D0/en
Publication of NO973404L publication Critical patent/NO973404L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Oppfirmelsen vedrører polynukleotider som koder for humant IL-1-receptor aksessorisk protein, isolert IL-1-receptor aksessorisk protein og antistoffer mot IL-1-receptor aksessorisk protein. Dette protein er spesielt nyttig ved forebyggelse av betennelser som skyldes innvirkningen av lL-1.The invention relates to polynucleotides encoding human IL-1 receptor accessory protein, isolated IL-1 receptor accessory protein and antibodies to IL-1 receptor accessory protein. This protein is particularly useful in preventing inflammation caused by the action of IL-1.

NO973404A 1995-01-23 1997-07-23 Human interleukin-1 receptor accessory protein NO973404L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37626895A 1995-01-23 1995-01-23
PCT/EP1996/000181 WO1996023067A1 (en) 1995-01-23 1996-01-17 Human interleukin-1 receptor accessory protein

Publications (2)

Publication Number Publication Date
NO973404D0 NO973404D0 (en) 1997-07-23
NO973404L true NO973404L (en) 1997-07-23

Family

ID=23484321

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973404A NO973404L (en) 1995-01-23 1997-07-23 Human interleukin-1 receptor accessory protein

Country Status (19)

Country Link
EP (1) EP0808365A1 (en)
JP (1) JPH10512453A (en)
AR (1) AR003919A1 (en)
AU (1) AU4537096A (en)
BR (1) BR9606837A (en)
CA (1) CA2210724A1 (en)
CO (1) CO4480033A1 (en)
CZ (1) CZ208197A3 (en)
EA (1) EA199700265A1 (en)
FI (1) FI973089A0 (en)
HU (1) HUP9702458A2 (en)
IL (1) IL116796A0 (en)
MX (1) MX9705501A (en)
NO (1) NO973404L (en)
PE (1) PE64396A1 (en)
PL (1) PL321538A1 (en)
TR (1) TR199700652T1 (en)
WO (1) WO1996023067A1 (en)
ZA (1) ZA96333B (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008969A1 (en) * 1996-08-26 1998-03-05 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
ES2312179T3 (en) 1996-12-06 2009-02-16 Amgen Inc. COMBINED THERAPY USING AN IL-1 INHIBITOR FOR THE TREATMENT OF ILL-1 ILLNESSES.
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
EP0979282A1 (en) * 1997-04-30 2000-02-16 F. Hoffmann-La Roche Ag Rat st38.2 chemokine
US6280955B1 (en) * 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
IL136696A0 (en) 1997-12-23 2001-06-14 Immunex Corp Sigirr dna and polypeptides
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2002064630A2 (en) * 2000-10-31 2002-08-22 Immunex Corporation Il-1 receptor accessory protein
GB2375604A (en) * 2001-05-18 2002-11-20 Warner Lambert Co Methods for screening using interleukin soluble trimolecular complex
EP2295081B1 (en) 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
KR100453877B1 (en) 2001-07-26 2004-10-20 메덱스젠 주식회사 METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR
US20030049255A1 (en) * 2001-08-07 2003-03-13 Sims John E. Interleukin-1 receptors in the treatment of diseases
KR101317045B1 (en) 2002-09-06 2013-10-16 암젠 인코포레이티드 Therapeutic human anti-il-1r1 monoclonal antibody
RS57852B1 (en) 2004-04-02 2018-12-31 Swedish Orphan Biovitrum Ab Publ Methods of reducing aggregation of il-1ra
EP1751175B1 (en) * 2004-05-05 2012-07-25 VALORISATION-RECHERCHE, Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
WO2007004060A2 (en) * 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
WO2009120905A2 (en) 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US9403906B2 (en) 2011-01-19 2016-08-02 Cantargia Ab Method of treatment of a solid tumor with interleukin-1 accessory protein antibody
RU2671980C2 (en) 2011-02-09 2018-11-08 Натера, Инк. Methods for non-invasive prenatal ploidy calling
CA2837651A1 (en) * 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
JP7114460B2 (en) * 2015-06-26 2022-08-08 サノフィ・バイオテクノロジー Monoclonal anti-IL-1RAcP antibody
RU2760913C2 (en) 2016-04-15 2021-12-01 Натера, Инк. Methods for identifying lung cancer
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
WO2018022982A1 (en) 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
US11773434B2 (en) 2017-06-20 2023-10-03 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free DNA
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
TW202021618A (en) 2018-08-17 2020-06-16 美商２３與我有限公司 Anti-il1rap antibodies and methods of use thereof
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2021236962A1 (en) 2020-05-20 2021-11-25 The Medical College Of Wisconsin, Inc. Compositions and methods for inhibiting cytokine-release syndrome
CN114835799A (en) * 2021-05-28 2022-08-02 百奥赛图江苏基因生物技术有限公司 Construction method and application of IL1RAP gene humanized non-human animal
AR130550A1 (en) 2022-09-21 2024-12-18 Sanofi Biotechnology HUMANIZED ANTI-IL-1R3 ANTIBODY AND METHODS OF USE

Also Published As

Publication number Publication date
CA2210724A1 (en) 1996-08-01
PE64396A1 (en) 1997-01-28
TR199700652T1 (en) 1998-02-21
EP0808365A1 (en) 1997-11-26
FI973089A7 (en) 1997-07-22
PL321538A1 (en) 1997-12-08
MX9705501A (en) 1997-10-31
CO4480033A1 (en) 1997-07-09
IL116796A0 (en) 1996-05-14
FI973089L (en) 1997-07-22
EA199700265A1 (en) 1998-04-30
WO1996023067A1 (en) 1996-08-01
FI973089A0 (en) 1997-07-22
ZA96333B (en) 1996-07-23
NO973404D0 (en) 1997-07-23
HUP9702458A2 (en) 1998-04-28
AU4537096A (en) 1996-08-14
CZ208197A3 (en) 1997-11-12
BR9606837A (en) 1998-05-26
AR003919A1 (en) 1998-09-30
JPH10512453A (en) 1998-12-02

Similar Documents

Publication Publication Date Title
NO973404L (en) Human interleukin-1 receptor accessory protein
EP0957722A4 (en) ADJUSTABLE ARMREST ASSEMBLY
DE69613753D1 (en) Dual output camshaft phase regulator
BR9609042A (en) Large crystal zsm-5 its synthesis and use
ES2193197T3 (en) CATALITIC CRAQUIZATION COM MCM-49.
DE59609792D1 (en) combustion chamber
IT1231727B (en) USEFUL PEPTIDES FOR THE DETERMINATION AND PURIFICATION OF ANTIBODIES INTERFERONE RANGE.
IT1284511B1 (en) BACK OF SAMPLES
NL1003627A1 (en) Conversion of aromatics and olefins.
KR970016042U (en) Armrest device of chair
KR970045914U (en) Desorption structure of the muffler for the piano
KR970039958U (en) Tappet of automotive valve mechanism
KR970031584U (en) Seat rotator of van
KR970031553U (en) Seat of van
KR970040145U (en) Exhaust of the engine
KR970040376U (en) Silencer structure
KR960032059U (en) Lighter combined use lighter
KR970040403U (en) Structure of Automotive Silencer
KR970040396U (en) Structure of Automotive Silencer
KR970022038U (en) Double Split Seat
KR940020798U (en) Odor Exhaust Structure of Toilet Seats
KR940020799U (en) Odor Exhaust Structure of Toilet Seats
KR970030922U (en) Handle structure of adjusting lever
KR970040724U (en) Exhaust structure of automobile
KR970043184U (en) Timing pulley structure of the engine